Oncopeptides Ab · OMXSTO:ONCO
Oncopeptides Ab — Investor Day (November 2020)
16 slides from Oncopeptides Ab's investor day presentation, Nov 30, 2020
Slide 1: Myeloma remains one of the largest unmet medical needs within hematology
Myeloma remains one of the largest unmet medical needs within hematology Josh Richter, MD Mount Sinai 1
Slide 2: Presentation at Oncopeptides Capital Markets Day, November 30, 2020
Presentation at Oncopeptides Capital Markets Day, November 30, 2020 Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
Slide 3: MM is the Second Most Common Hematologic Malignancy After Lymphoma
MM is the Second Most Common Hematologic Malignancy After Lymphoma1 40 35 30.8 Percent of New Cases 30 MM accounts for 1.8% of all new cancer cases in the US2 Percent of 23.3 25 22.9 • Incidence of MM has steadily increased over the past new cases 20 15 years in the US by age 15 • Estimated prevalen
Slide 4: Even with Advances in Treatment Myeloma Continues to Have One of the Worst Prognoses
Even with Advances in Treatment Myeloma Continues to Have One of the Worst Prognoses of Hematological Malignancies 90 80 MDS CLL 70 AML MM NHL Medium Age at Diagnosis CML MPNs 60 50 Incidence Scale 40 83,000 All (Age 20+) HL 2,800 30 20 All (Age <20) 10 0 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Slide 5: How Multiple Myeloma is Treated
How Multiple Myeloma is Treated Four therapeutic drug classes are used in the majority Triple-class refractory MM1 of treatments for patients with MM1 • Growing number of patients exposed to PIs, IMiDs, • Resistance to each subsequent line of treatment and anti-CD38 agents is inevitable, due to clon
Slide 6: Choosing Therapies for Myeloma
Choosing Therapies for Myeloma Proteasome IMiDs Anthracyclines Alkylators Steroids HDACi Antibodies SINE Inhibitors Thalidomide Bortezomib Doxil Melphalan Dexamethasone Panobinostat Elotuzumab Selinexor Lenalidomide Carfilzomib Cytoxan Prednisone Daratumumab Bendamustin Pomalidomide Ixazomib Solumed
Slide 7: Once Treatment Fails Trouble Begins
Once Treatment Fails Trouble Begins Overall Survival From Start of Therapy Survival with Btz/Len Refractory Ds by Regimen Number Median Events/N (Months) 1.0 Cumulative Probability (%) 100 Overall Survival 170/286 9 (7, 11) Regimen 1 0.8 Regimen 2 Event-Free Survival 217/286 5 (4, 6) Regimen 3 80 Su
Slide 8: Sequencing Strategies
Sequencing Strategies Chim, et al. Leukemia (2018) 32, 252–262 8
Slide 9: Fragmented RRMM Regimens Used in a Real-world Setting
Fragmented RRMM Regimens Used in a Real-world Setting 55% Regimens are Singlet/Doublet Therapy (2L+) Top RRMM regimen patient share based on EMR database 15,0% Singlet/Doublet Triplet Pomalyst ± Dex Darzalex ± Dex 10,0% RVd Revlimid ± Dex Ninlaro ± Dex 5,0% Kyprolis ± Dex DVd Velcade ± Dex DPd 0,0%
Slide 10: There is an Unmet Medical Need for Patients with RRMM
There is an Unmet Medical Need for Patients with RRMM Later Line Patient Population Growing with Need for New Treatments Patients by Line of Therapy – Non-SCT (U.S.) 100% Normal Population 80% Total Patient Share (%) 60% Medical Need Myeloma in Myeloma 40% 20% 0% 1L 2L 3L 4L Source: Kantar Health 20
Slide 11: Multiple Myeloma: Patient Outcomes in Real-World Practice
Multiple Myeloma: Patient Outcomes in Real‐World Practice Treatment Duration and Treatment-Free Interval by Line of Therapy* Proportion of patients reaching Treatment-free interval this line of therapy (%) Active treatment Maintenance treatment 100% Diagnosis Median duration in months shown 1m 6m 6m
Slide 12: Triple-class Refractory Patients Are Growing Quickly and Occurring Earlier in RRMM
Triple-class Refractory Patients Are Growing Quickly and Occurring Earlier in RRMM Triple-class refractory patients entering each LoT 100,0% 80,0% 67% 66% 61% % of LoT 60,0% 40,0% 34% 34% 20% 17% 20,0% 13% 9% 0,0%0,4% 3% 0,0% 2L 3L 4L 5L 2012-2014 Dx 2015-2017 Dx 2018-2020 Dx Source: Oncopeptides ma
Slide 13: Classical Chemotherapy in Quad- and Penta-Refractory Myeloma
Classical Chemotherapy in Quad- and Penta- Refractory Myeloma Goldsmith, et al. Annals of Hematology (2020) 99:1041–1048 13
Slide 14: HORIZON: Registrational Trial for Accelerated Approval
HORIZON: Registrational Trial for Accelerated Approval Phase 2, Single-Arm, Open-Label, Multicenter Study (EoT Melflufen 40 mg + dex 40 mga PFS and OS follow-up Adult patients with ) (Until disease progression or unacceptable toxicity) for ≤24 mo RR MM refractory to pom or Primary endpoint anti-CD38
Slide 15: HORIZON Study Results: Summary of Outcomes (ITT)
HORIZON Study Results: Summary of Outcomes (ITT) ORR: Patients in the Who Achieved a PR or Better Primary endpoint (95%CI) • ORR: 29% (22-37) Secondary endpoints (95%CI) • DOR: 5.5m (3.4-7.6) • CBR: 45% (37-53) • PFS: 4.2m (3.4-4.9) • OS: 11.6m (9.3-15.4) • mPFS in responders 8.5m Safety (% all Grad
Slide 16: What a New Treatment Option Would Mean For My Clinic
What a New Treatment Option Would Mean For My Clinic • In the Horizon Trial, Melphalan Flufenamide demonstrated clinically meaningful efficacy and a manageable safety profile in heavily pretreated relapsed refractory multiple myeloma patients • An effective alkylator-based option for patients who en